Virax Biolabs Group Limited (VRAX)
(Delayed Data from NSDQ)
$0.78 USD
-0.01 (-0.78%)
Updated Aug 8, 2025 03:40 PM ET
After-Market: $0.79 +0.01 (0.78%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VRAX 0.78 -0.01(-0.78%)
Will VRAX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VRAX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRAX
Zacks Investment Ideas feature highlights: Virax Biolabs Group, GeoVax Labs, Applied DNA Sciences and Emergent BioSolutions
WHO Declares Monkeypox Public Emergency: 5 Mpox Stocks to Watch
VRAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for VRAX
Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial ...
Virax Biolabs (VRAX) Faces Nasdaq Compliance Challenge | VRAX Stock News
Virax Biolabs receives noncompliance notice from Nasdaq
Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price ...
Virax Biolabs receives Nasdaq letter over non-compliance with minimum bid price rule